☰

Xuehua Ke, Ph.D. - Publications

Affiliations: 
2014 Pharmaceutical Health Services Research University of Maryland School of Medicine, Baltimore, MD, United States 
Area:
Health Care Management, Pharmacy, Oncology
Tree Info Similar researchers PubMed Report error

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Davidoff AJ, Gardner LD, Zuckerman IH, Hendrick F, Ke X, Edelman MJ. Validation of disability status, a claims-based measure of functional status for cancer treatment and outcomes studies. Medical Care. 52: 500-10. PMID 24638118 DOI: 10.1097/Mlr.0000000000000122  0.425
2014 Erten MZ, Davidoff AJ, Zuckerman IH, Shaffer T, Dougherty JS, Ke X, Stuart B. The effect of supplemental medical and prescription drug coverage on health care spending for Medicare beneficiaries with cancer. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 17: 15-21. PMID 24438713 DOI: 10.1016/J.Jval.2013.11.003  0.584
2013 Davidoff AJ, Zuckerman IH, Pandya N, Hendrick F, Ke X, Hurria A, Lichtman SM, Hussain A, Weiner JP, Edelman MJ. A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. Journal of Geriatric Oncology. 4: 157-65. PMID 23795223 DOI: 10.1016/J.Jgo.2012.12.005  0.403
2013 Davidoff AJ, Weiss SR, Baer MR, Ke X, Hendrick F, Zeidan A, Gore SD. Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines. Leukemia Research. 37: 675-80. PMID 23523473 DOI: 10.1016/J.Leukres.2013.02.021  0.325
2013 Davidoff AJ, Erten M, Shaffer T, Shoemaker JS, Zuckerman IH, Pandya N, Tai MH, Ke X, Stuart B. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer. 119: 1257-65. PMID 23225522 DOI: 10.1002/Cncr.27848  0.592
2013 Zandberg DP, Huang TY, Ke X, Baer MR, Gore SD, Smith SW, Davidoff AJ. Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults. Haematologica. 98: 584-90. PMID 23144192 DOI: 10.3324/Haematol.2012.062547  0.319
2012 Davidoff AJ, Weiss Smith S, Baer MR, Ke X, Bierenbaum JM, Hendrick F, McNally DL, Gore SD. Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes. Haematologica. 97: 128-32. PMID 22210329 DOI: 10.3324/Haematol.2011.049130  0.347
2012 Smith SW, Sato M, Gore SD, Baer MR, Ke X, McNally D, Davidoff A. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes. Haematologica. 97: 15-20. PMID 22102702 DOI: 10.3324/Haematol.2011.051755  0.333
2012 Zuckerman IH, Pandya NB, Stuart BC, Shaffer T, Erten MZ, Ke X, Shoemaker JS, Tai M, Davidoff AJ. Out-of-pocket (OOP) health care expenditure burden for Medicare beneficiaries with cancer. Journal of Clinical Oncology. 30: 6075-6075. DOI: 10.1200/Jco.2012.30.15_Suppl.6075  0.57
2012 Ke X, Zuckerman IH, Pandya NB, Shaffer T, Snyder CF, Stuart BC, Davidoff AJ. How do elderly cancer survivors fare? A comparison of characteristics, health status, health behaviors, and spending between Medicare beneficiaries with and without a cancer history. Journal of Clinical Oncology. 30: 6028-6028. DOI: 10.1200/Jco.2012.30.15_Suppl.6028  0.52
2011 Hendrick F, Zuckerman IH, Pandya NB, Ke X, Edelman MJ, Davidoff AJ. Validation of a claims-based predicted performance status measure in SEER-Medicare. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6085. PMID 28021771 DOI: 10.1200/Jco.2011.29.15_Suppl.6085  0.396
2011 Davidoff AJ, Ke X, Baer MR, Smith SRW, Zandberg D, Hendrick F, Sato M, Greenberg PL, Gore SD. Do Erythropoiesis-Stimulating Agents (ESAs) Affect Survival in Anemic Patients with Myelodysplastic Syndromes (MDS)? Blood. 118: 2794-2794. DOI: 10.1182/Blood.V118.21.2794.2794  0.37
2011 Zandberg D, Huang T, Ke X, Baer MR, Gore SD, Smith SW, Davidoff AJ. Chronic Myelomonocytic Leukemia Is Associated with More Frequent and More Rapid Progression to Acute Myeloid Leukemia and Shorter Survival Than Myelodysplastic Syndrome, but Is Less Frequently Treated: Analysis of Surveillance Epidemiology and End Results Data Linked to Medicare Enrollment Claims Blood. 118: 2784-2784. DOI: 10.1182/Blood.V118.21.2784.2784  0.35
2011 Ke X, Davidoff A, Zuckerman I, Pandya N, Hendrick F, Smith SW, Baer M, Gore S. 146 Claims-based prediction of performance status (PS) associated with erythropoietic-stimulating agent (ESA) treatment and survival in myelodysplastic syndromes (MDS) patients Leukemia Research. 35: S57. DOI: 10.1016/S0145-2126(11)70148-5  0.328
2010 Ke X, Hendrick F, Shaffer T, Davidoff AJ. Out-of-pocket (OOP) spending burden for Medicare beneficiaries with cancer. Journal of Clinical Oncology. 28: 9124-9124. DOI: 10.1200/Jco.2010.28.15_Suppl.9124  0.427
2010 Davidoff AJ, Zuckerman IH, Pandya NB, Hendrick F, Ke X, Hurria A, Lichtman SM, Hussain A, Edelman MJ. Development of a performance status prediction model for use in administrative data analyses. Journal of Clinical Oncology. 28: 6006-6006. DOI: 10.1200/Jco.2010.28.15_Suppl.6006  0.358
2010 Davidoff AJ, Smith SW, Baer MR, Ke X, Bierenbaum JM, Hendrick F, McNally DL, Gore SD. Access to Care, Race and Education Are Key Determinants of Erythropoietin Stimulating Agent (ESA) Use In Myelodysplastic Syndromes (MDS). Blood. 116: 3815-3815. DOI: 10.1182/Blood.V116.21.3815.3815  0.366
Show low-probability matches.